Billiontoone (NASDAQ:BLLN) Insider Shan Riku Sakakibara Sells 8,000 Shares

Posted by Brian Himes on Jun 11th, 2026

Billiontoone, Inc. (NASDAQ:BLLN – Get Free Report) insider Shan Riku Sakakibara sold 8,000 shares of Billiontoone stock in a transaction dated Monday, June 8th. The shares were sold at an average price of $98.22, for a total transaction of $785,760.00. Following the sale, the insider owned 212,000 shares of the company’s stock, valued at $20,822,640. The trade was a 3.64% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Billiontoone Trading Down 3.1%

Shares of BLLN opened at $99.26 on Thursday. Billiontoone, Inc. has a 1-year low of $61.96 and a 1-year high of $138.70. The company has a 50-day moving average of $87.26 and a 200 day moving average of $88.18. The firm has a market capitalization of $4.57 billion and a price-to-earnings ratio of 180.47. The company has a debt-to-equity ratio of 0.18, a current ratio of 10.92 and a quick ratio of 10.58.

Billiontoone (NASDAQ:BLLN – Get Free Report) last posted its quarterly earnings results on Wednesday, May 6th. The company reported $0.34 earnings per share for the quarter, beating the consensus estimate of $0.01 by $0.33. The company had revenue of $108.39 million for the quarter, compared to the consensus estimate of $95.81 million. During the same period in the prior year, the firm posted ($0.39) EPS. The business’s revenue was up 83.8% on a year-over-year basis. On average, research analysts expect that Billiontoone, Inc. will post 0.93 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on BLLN. Wells Fargo & Company lowered their target price on shares of Billiontoone from $110.00 to $90.00 and set an “equal weight” rating for the company in a research note on Thursday, March 5th. BTIG Research decreased their price objective on shares of Billiontoone from $140.00 to $130.00 and set a “buy” rating for the company in a research note on Thursday, May 7th. JPMorgan Chase & Co. lifted their price objective on shares of Billiontoone from $120.00 to $125.00 and gave the company an “overweight” rating in a research note on Thursday, May 7th. Guggenheim lifted their price objective on shares of Billiontoone from $100.00 to $120.00 and gave the company a “buy” rating in a research note on Wednesday, May 13th. Finally, Wall Street Zen upgraded shares of Billiontoone from a “hold” rating to a “buy” rating in a research note on Saturday, March 7th. Six research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $125.29.

Check Out Our Latest Analysis on BLLN

Hedge Funds Weigh In On Billiontoone

Large investors have recently made changes to their positions in the company. Rossby Financial LCC acquired a new position in shares of Billiontoone in the 4th quarter valued at $25,000. Wells Fargo & Company MN acquired a new position in Billiontoone during the fourth quarter worth $76,000. Smartleaf Asset Management LLC acquired a new position in Billiontoone during the fourth quarter worth $80,000. Nano Cap New Millennium Growth Fund L P acquired a new position in Billiontoone during the fourth quarter worth $82,000. Finally, Renaissance Capital LLC acquired a new position in Billiontoone during the fourth quarter worth $201,000.

About Billiontoone

(Get Free Report)

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.